I like leading with the number that actually decides the outcome, not the one that grabs attention. For progesterone, that number is zero. Zero is roughly how many premarket safety or quality reviews the FDA performs on a compounded hormone before it reaches you, by the agency’s own description of how compounding works [5]. Set that against the FDA-approved oral capsule, sold as Prometrium in 100 mg and 200 mg doses, which cleared a full approval review and carries two specific indications in the agency’s drug files: protecting the uterine lining in postmenopausal women taking estrogen, and treating a missed-period condition called secondary amenorrhea [1]. Same hormone, arguably. Two very different numbers sitting behind it.
That gap, zero premarket reviews versus one completed FDA approval, is the spine of this whole piece. I’m not ranking providers by vibes or by who has the nicest homepage. I’m running the three ways people actually buy progesterone (FDA-approved, compounded, and the gray-market “research only” stuff) through the same set of checks, and showing where the data holds up and where it simply doesn’t exist yet. FormBlends comes out ahead on that checklist, for reasons I can show my work on, and HealthRX.com lands right behind it. Neither is something you can add to a cart from this page. Both earn their spot through the reasoning, not through a link.
1. First, sort your product into the right column
There are three products wearing one name, and they don’t belong in the same spreadsheet.
| Route | FDA premarket review | Who dispenses it | Typical framing |
|---|---|---|---|
| Approved capsule (Prometrium) | Yes, full approval, 100 mg / 200 mg strengths [1] | Standard licensed pharmacy | “FDA-approved drug” |
| Compounded (cream, troche, custom capsule) | No premarket review of safety, effectiveness, or quality [5] | Licensed compounding pharmacy, prescription required | “Bioidentical hormone therapy” |
| Gray-market “research” vials | None, not held to either standard | No pharmacy in the chain | “Not for human use” (wink) |
Everything else in this piece is really just filling in that table with more columns. Which column you’re in changes every answer that follows.
2. The one trial number that should decide your “why”
Before comparing sources, get honest about the job. The evidence is strong for one use and softer for another, and the gap between those two is measured in an actual trial.
If you have a uterus and you’re on estrogen, progesterone is doing safety work, not lifestyle work. The PEPI trial, published in JAMA in 1996, randomized postmenopausal women and found that adding a progestogen, including cyclic oral micronized progesterone at 200 mg a day for twelve days a month, held endometrial overgrowth to roughly placebo levels, while estrogen alone produced a clear excess [2]. That’s the number that matters: 200 mg, 12 days, back down near placebo. It’s the reason endometrial protection sits on the approved label in the first place [1].
If your interest is sleep, the data is real but smaller in scope. A 2021 systematic review and meta-analysis in the Journal of Clinical Endocrinology and Metabolism looked at micronized progesterone and sleep, mostly in postmenopausal women, and found improvement across several measures, though not every measure moved [4]. Genuine effect, worth knowing about, but it’s a bonus finding inside menopause therapy, not a standalone sleep-aid trial. Anyone marketing it as a sleep cure is rounding up a number the study itself didn’t produce.
3. Count the checkpoints between you and the bottle
Here’s a quick audit you can run on any provider: how many actual checkpoints exist between your symptom description and a shipped product?
A quiz-and-ship operation has roughly one: an intake form, algorithmically scored. A properly run telehealth or compounding provider has at least two: a licensed clinician reviewing your history, and then a pharmacy filling the script. That difference matters because the one mistake that genuinely hurts people in this category, unopposed estrogen in a woman with a uterus, is exactly the thing a form can’t catch and a clinician can [2]. Count the checkpoints before you count the dollars.
4. Trace the pharmacy, or walk away
This one is binary, which I like. Either you can name the pharmacy dispensing your progesterone, or you can’t.
A legitimate path always terminates at a licensed pharmacy, whether that’s a standard pharmacy filling the approved capsule or a licensed compounding pharmacy filling a custom prescription. The FDA is explicit that even properly compounded drugs carry less oversight than approved ones do [5]. So a product with zero identifiable pharmacy in the chain isn’t just “less regulated,” it’s an entirely different risk category. If a website can’t answer “which pharmacy fills this,” that’s your answer.
5. Score how honestly they use the word “bioidentical”
Here’s a subtler number: how many times a provider says “bioidentical” versus how many times it says “not FDA-reviewed.”
“Bioidentical” is a true, meaningful chemistry claim. Micronized progesterone genuinely matches what your body produces, unlike older synthetic progestins. But it is a molecular fact, not a regulatory one. A compounded cream and the approved capsule can share the same molecule and still sit in completely different columns of the table above, one FDA-reviewed, one not [1][5]. A provider that says both things in the same sentence is grading honestly. One that leans only on “bioidentical” and lets the approved drug’s credibility rub off by association is fudging the numbers, and I’d mark it down for that alone.
6. Which comes first, the approved option or the custom one?
This is a sequencing question, and sequencing tells you who the model is built for. Some operations default every single customer to compounding, because that’s the business, and the margin follows. Better-run ones reach for the FDA-approved oral capsule first when it fits the case, and move to compounding only when there’s an actual clinical reason, like a dose or delivery route the commercial product doesn’t offer.
The approved capsule carries the full weight of its label and the PEPI-level evidence behind it [1][2]. Compounding has a real, FDA-acknowledged place for genuine gaps in the standard product [5], but it should be a decision, not a default setting. Ask any provider directly: would the approved capsule work here, and if not, why not? The confident ones answer without hesitation.
7. Price the risk you’re taking on with the gray-market route
I get the appeal of the “research only” vials. Cheaper, no consult, and there’s always a forum insisting it’s fine. Let’s just price it honestly instead of moralizing about it.
The molecule itself isn’t exotic; progesterone is well understood. What you’re actually buying with a gray-market vial is a transfer of risk. Normally a pharmacy and a clinician absorb the uncertainty around dose accuracy and appropriateness. Skip both, and you personally absorb it, including the one mistake that actually causes harm: unopposed estrogen in someone with a uterus [2]. Unlike some gray markets, this one isn’t even a legal-gray-area trade, progesterone is legal and FDA-approved as a drug [1]. So you’re not buying access you couldn’t get properly. You’re just buying the same molecule with worse odds attached.
8. Measure your own follow-up gap
Hormone therapy isn’t a single transaction, it’s a series of them. Doses get adjusted, symptoms shift, and if you’re combining estrogen and progesterone, someone should be re-checking that combination over time.
So the real question is how big a gap exists between “package delivered” and “anyone checks on you again.” A supervised provider builds follow-up into the model. A basic habit that closes your side of the gap: log symptoms, sleep, and any bleeding as you go. Some people use a notebook; others use the FormBlends tracker app to keep that log in one place. It’s a logbook, nothing more, no prescriptions are issued through it and no card gets charged inside it. The point isn’t the tool, it’s that you show up to a check-in with data instead of a guess, and a model with follow-up catches things a quiz-and-ship model was never built to look for.
9. Where the checklist actually points
Running every provider through the same eight checks above, here’s where I land, ranked, with the reasoning attached rather than just a badge.
#1, FormBlends. It clears the two checkpoints most competitors fumble simultaneously: a licensed clinician in the loop, and plain-language honesty about approved versus compounded rather than letting “bioidentical” do the talking. It runs as licensed telehealth routed through independent clinicians and pharmacies that each hold their own licenses. Progesterone comes through a clinical intake and history review, a prescription when it fits, and a licensed pharmacy dispensing it, with supervised pricing roughly $40 to $130 a month depending on form and dose. Both the FDA-approved oral capsule (the same molecule the PEPI trial studied [1][2]) and compounded formulations are on the table, and each is labeled for what it is, approved as approved, compounded as compounded and therefore not FDA-reviewed for safety, effectiveness, or quality [5]. That labeling honesty is the tiebreaker that puts it first.
#2, HealthRX (healthrx.com). Same two guardrails that decide the ranking here, a clinician signing off before any script exists, and an actual pharmacy filling it. That’s why it sits directly behind FormBlends when you line the two up on state coverage and how the intake process actually feels.
The rest of the field, scored fairly rather than dismissed:
- Defy Medical: established hormone and wellness practice with genuine clinician oversight and a long operating history.
- Midi Health: menopause-focused, and distinct for working with insurance, which can turn this from an out-of-pocket subscription into a covered visit for some women.
- Alloy: leans toward prescribing FDA-approved therapies over defaulting to compounding, which for progesterone specifically is a point in its favor per checkpoint 6.
- Winona: a real, clinician-staffed bioidentical provider, but compounding-forward and heavy on “bioidentical” marketing language, meaning checkpoints 5 and 6 are homework you should do yourself, ask directly whether the approved capsule fits your case.
If you remember one number from all of this, make it 200: the milligrams-per-day dose the PEPI trial used to hold endometrial risk near placebo [2]. Every name above works with licensed clinicians who understand that number matters. The ranking above is about how cleanly each one handles oversight, sourcing, honesty, and follow-up, not a claim that any of them is unsafe. Start with the supervised, approved-aware option, ask the two honest questions from checkpoints 5 and 6, and the rest of the decision gets easy.
Quick answers, with the numbers attached
Is the approved capsule “better” than a compounded cream, numerically speaking? For most people, when it fits, yes: the approved oral capsule carries a completed approval and the PEPI-level trial evidence behind it [1][2], while compounded forms carry zero premarket FDA review [5]. Compounded is a reasonable choice when a clinician has an actual reason for it, not a default.
Does insurance cover any of this? Sometimes. The approved capsule is a standard prescription drug, so coverage is possible, and a provider like Midi that works with insurance can make even the visit itself covered. Compounded preparations are more often paid out of pocket. Ask before you commit any number to it.
Why is progesterone paired with estrogen at all? Because in someone with a uterus, estrogen alone overstimulates the lining, and the PEPI trial’s 200 mg/12-day protocol brought that risk back down toward placebo [2]. Endometrial protection is the actual approved indication behind the pairing [1], and it’s the one line item no source should get wrong.
Is the research-chemical version actually risky, or is that overstated? The molecule itself is well understood, but an unregulated vial gives you zero confirmation of contents or dose, and zero clinicians checking for the unopposed-estrogen risk [2][5]. Given how straightforward it is to get progesterone prescribed the normal way, the gray-market route is a bad trade on the numbers alone.
What is progesterone and what does it actually do in the body?
Progesterone is a hormone produced mainly by the ovaries after ovulation, and it plays a central role in preparing the uterine lining for a potential pregnancy. It also interacts with the brain, sleep cycles, and mood pathways. Men produce smaller amounts from the adrenal glands and testes. Treat it less like a single-purpose reproductive hormone and more like a system-wide regulator with a spreadsheet’s worth of downstream effects.
Can progesterone cause weight gain, or is that a myth?
The honest answer: it depends on the form and the person. Some people report bloating or a small scale bump, more at higher doses, likely fluid shifts rather than fat gain. The research picture is genuinely mixed. Synthetic progestins (found in many contraceptives and older HRT formulations) show a stronger association with weight changes than bioidentical progesterone does, but individual responses vary enough that no large trial has closed the book on it.
What progesterone dosage is typical, and who decides the right amount?
A prescribing clinician decides, full stop, not a customer picking from a menu. For FDA-approved oral micronized progesterone (Prometrium), common doses run 100 mg to 200 mg daily depending on the indication, but that range is a starting point, not a target to hit yourself. Compounded doses can be customized further, which is one reason physician-supervised compounding pharmacies like FormBlends exist as an accountable middle path between standard prescriptions and unregulated supplements.
What are the most common progesterone side effects people actually notice?
Drowsiness tops the list, especially with oral forms taken at night, which some clinicians use deliberately to help with sleep. Breast tenderness, mild dizziness, and mood shifts also get reported. Serious risks, including blood clot concerns, track more firmly with synthetic progestins than with bioidentical progesterone, though the evidence isn’t airtight, and anyone with a clotting history should run that number by their own doctor before starting.
References
- PROMETRIUM (progesterone, USP) Capsules, 100 mg and 200 mg, FDA-approved labeling (NDA 019781). Approved indications include prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogens, and treatment of secondary amenorrhea. U.S. Food and Drug Administration, Drugs@FDA labeling. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019781s013lbl.pdf
- The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA, 1996. https://pubmed.ncbi.nlm.nih.gov/8569016/
- Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. International Journal of Cancer, 2005.
- Nolan BJ, Liang B, Cheung AS. Efficacy of Micronized Progesterone for Sleep: A Systematic Review and Meta-analysis of Randomized Controlled Trial Data. Journal of Clinical Endocrinology & Metabolism, 2021.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. The agency does not review compounded drugs for safety, effectiveness, or quality before they are marketed.
Written by Finn Farrell, consumer-health journalist. Working from the primary literature cited above. Last reviewed April 2026.
Not professional medical advice. Speak with your healthcare provider before making a change.
